GNMSF (Genmab AS) Issuance of Debt: $0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNMSF Genmab AS GNMSF
95 GF Score
Price $310.63
GF Value $351.55
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Issuance of Debt?

Genmab AS GNMSF 95 Issuance of Debt is $0 Mil as of Jun. 2026. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $351.55 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Genmab AS's Issuance of Debt for the three months ended in Jun. 2026 was $0 Mil.

Genmab AS's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0 Mil.

Genmab AS Issuance of Debt Related Terms

Genmab AS Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Genmab AS's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Issuance of Debt Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GNMSF
95GF Score
Genmab AS GNMSF
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0 Mil mean?
Genmab AS (GNMSF) has a Issuance of Debt of $0 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Genmab AS and its competitors.
Is Genmab AS's Issuance of Debt too high?
Genmab AS's current Issuance of Debt is $0 Mil. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Issuance of Debt compare to VRTX and REGN?
Genmab AS's Issuance of Debt of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Genmab AS and its competitors. Genmab AS's current Issuance of Debt is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $351.55, compared to a current price of $310.63 — trading 11.6% below its estimated fair value. The current Issuance of Debt is $0 Mil. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Issuance of Debt is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $310.63 is trading 11.6% below its estimated GF Value™ of $351.55. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Issuance of Debt: $0 Mil
  • GF Value™: $351.55 vs. price of $310.63 (11.6% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for GNMSF

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$310.63
Price
$351.55
GF Value